Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

The European Respiratory Journal makes COPD a priority

J.B. Soriano, V. Brusasco, A.T. Dinh-Xuan
European Respiratory Journal 2011 38: 999-1001; DOI: 10.1183/09031936.00055711
J.B. Soriano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jbsoriano@caubet-cimera.es
V. Brusasco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A.T. Dinh-Xuan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Chronic obstructive pulmonary disease (COPD) represents a major problem for public health worldwide and its burden is expected to increase in the next decade. Despite the extensive resources invested in research and the wealth of studies published in leading scientific journals, there are still many unknown aspects regarding the nature of COPD, which make this disease difficult to treat. A number of authors and societies have recently outlined some of the burning questions on COPD that need to be addressed by researchers in order to reduce the burden of the disease and help funding agencies to prioritise limited resources in competitive calls. They include documents from the American Thoracic Society (ATS)/European Respiratory Society (ERS) [1, 2], the Global Alliance against Chronic Respiratory Diseases (GARD) [3], the International Primary Care Research Group [4] and the American Journal of Respiratory and Critical Care Medicine [5, 6].

The number of indexed respiratory journals has substantially increased in the past few years and some also incorporate COPD in their title, which allows more room for articles on this disease. The European Respiratory Journal (ERJ) has already published many papers on COPD and is eager to publish more, and better, research on this topic in the near future. However, we must keep in mind that space is limited and the competition for priority is tough among manuscripts in different fields. The ERJ can currently accept less than 15% of submitted manuscripts, and immediate rejection without external peer review is becoming a painful but necessary measure given the overload of manuscripts not focused on sufficiently relevant questions. We understand that, after the time-consuming task of formatting text, tables and figures, collecting signed forms, and then uploading it all in a web server, no one enjoys a same-day response of “No thanks”.

In this editorial we highlight some topics and questions we consider of the highest relevance in COPD research and worth the utmost consideration by the ERJ editorial team. Needless to say that scientific merit remains the fundamental determinant of the final accept or reject decision in any given submission [7, 8]. We hope that helping future authors to direct their manuscripts to these topics will ultimately produce the mutual benefit to both them and ourselves, as their messages will be promptly disseminated and the journal will maintain or even increase its profile and prestige [9]. The COPD research topics that would be most welcome by the ERJ editors are summarised in table 1 and are briefly covered in the following text by areas.

View this table:
  • View inline
  • View popup
Table 1– List of chronic obstructive pulmonary disease (COPD) topics and related questions of particular interest to the European Respiratory Journal

DIAGNOSIS

Ever since the early Ciba symposia, the diagnosis of obstructive respiratory diseases has been considered a challenge. This is mainly because of the overlap between asthma and COPD and the wide variability of lung function in the general population. In addition, the long-standing lack of lung function tests sensitive to abnormalities in small airways makes the diagnosis of COPD difficult in the early stages, when only the so-called “silent zone” of the lung is involved. Further research on the detection of early abnormalities by means of noninvasive (or minimally invasive) methods sensitive and/or specific enough to find early morphological changes in airways and/or lung parenchyma is badly required. The question of how to define COPD has been polarising researchers for decades, and it appears that new evidence separates further rather than produces nearer agreement. Advantages, disadvantages and quantification of the effectiveness of different definitions are to be researched. Beyond the endless argument on spirometry criteria, there is a need to determine which are the best functional and clinical predictors of individual and group morbidity/mortality, in order to find the best definition of the disease. In this context, monitoring of disease progression by lung function (and other domains) in relation to initial clinical or physiological characteristics and according to phenotypes will be welcome.

EPIDEMIOLOGY

Following the well-established public health principle, “to measure a health problem is the first step to identify a strategy to tackle it,” the spread of the burden of COPD is, and will remain, a hot topic. More data on how frequent COPD is in low income (and middle and high income) countries with “blank” data of chronic lung disease are needed, as well as on the homogeneity of its distribution (or lack of it) in time and place, and all issues on comorbidities. Tobacco is the first and foremost causal risk factor for COPD, and perhaps it has been neglected too often in the past in many respiratory venues. We emphasise that we welcome submissions on key tobacco-related translational issues, and on the efficacy and the effectiveness of any smoking reduction and/or avoidance interventions, as well as on any other risk factors to help define it at the population and individual levels. Predicting the future is difficult, but more national and international data to estimate the future COPD and tobacco burden are also welcome. The use of any lung function assessment, single or serial, alone or combined in multi-dimensional scores, aimed to screen, label and determine severity of COPD needs to be assessed with care.

BASIC SCIENCE

Even for the fully practising physician, dissemination of basic science research results is considered fundamental and formative. Thus, papers on mechanisms responsible for lung damage, susceptibility to infections and remodelling of the different components of lung architecture, and other are also welcome. Answers to what are the mechanisms by which COPD manifests in only less than half of subjects exposed to risk factors are desperately needed. An old term which is newly applied in COPD is phenotyping; that is, identifying different manifestations of the disease in individual patients. This can be done by clustering patients using both clinical and statistical criteria with measurements that are sensitive to different types/localisations of the underlying pathology. In terms of basic science, relevant questions need to be answered regarding why some patients develop predominantly small airway disease while others develop emphysema, and the role of distinct pathological traits in different clinical phenotypes (centrilobular versus panlobular emphysema), of airway smooth muscle versus whole airway remodelling and of mucous hypersecretion in the pathogenesis of COPD. Finally, the mechanism(s) underlying the development of abnormalities in organs other than the lungs are also of interest. Integration of basic science and all the “omics” data, with systems biology or other computer tools, holds potential in this field.

DRUGS AND TREATMENTS

Being a clinical journal, the ERJ welcomes papers on efficacy, safety and effectiveness of current and new drugs. Application of these drugs in all patients has been the target of several large clinical trials, which are welcomed by both respiratory and general journals. Studies looking at the effects of drug treatments in subsets of specific phenotypes are, however, lacking, and so are studies on the effects of comorbidities on the response to different treatments. This is a question that needs to be addressed if we want to know whether treatment outcomes are the same in respiratory services, internal medicine or primary care. In the end, both standard, randomised, double-blind trials in many hundreds or even thousands of “pure” COPD patients, and more “real life” pragmatic trials will be needed [10]. Last but not least, consider the ERJ when reporting on anything else reducing COPD exacerbations, from symptom-defined up to those requiring hospital admissions and their associated burden and costs.

When an investigator applies for funding, the main goal is to obtain money for conducting his/her research. Later, any potential author wants his/her research papers accepted in the best possible journal, and on time. We do hope that by guiding potential COPD authors to the ERJ, the benefit and gains are mutual. Journals can be considered as living entities. They indeed evolve with time and respond to change. Some become extinct. Survival of the fittest rules in the jungle of COPD research. Only by adapting to this new, more competitive environment in the struggle for the best COPD manuscripts will our beloved ERJ better serve our readers and the society.

Acknowledgments

We thank N. Ambrosino, M. Polkey and M. Saetta for their comments and input.

Footnotes

  • Statement of Interest

    A statement of interest for V. Brusasco can be found at www.erj.ersjournals.com/site/misc/statements.xhtml

  • ©ERS 2011

REFERENCES

  1. ↵
    1. Cazzola M,
    2. MacNee W,
    3. Martinez FJ,
    4. et al
    . Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416–469.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    European Respiratory Society/European Lung Foundation. European Lung White Book. Sheffield, European Respiratory Society Journals Ltd, 2003.
  3. ↵
    1. Bousquet J,
    2. Kiley J,
    3. Bateman ED,
    4. et al
    . Prioritised research agenda for prevention and control of chronic respiratory diseases. Eur Respir J 2010; 36: 995–1001.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Pinnock H,
    2. Thomas M,
    3. Tsiligianni I,
    4. et al
    . The International Primary Care Respiratory Group (IPCRG) Research Needs Statement 2010. Prim Care Respir J 2010; 19: Suppl. 1, S1–S20. http://dx.doi.org/10.4104/pcrj.2010.00021
    OpenUrlCrossRef
  5. ↵
    1. Agusti A,
    2. Barnes PJ
    . What the journal would like to publish on chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182: 1–2.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Han MK,
    2. Agusti A,
    3. Calverley PM,
    4. et al
    . COPD phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 582: 598–604.
    OpenUrl
  7. ↵
    1. Dinh-Xuan AT,
    2. Brusasco V
    . Refining the changes. Or, how to modify the shape, not the spirit. Eur Respir J 2009; 34: 1.
    OpenUrlFREE Full Text
  8. ↵
    1. Migliori GB,
    2. Soriano JB Brusasco V,
    3. et al
    . ERJ peer reviewers: does this pillar of the Journal's quality need help?. Eur Respir J 2011; 38: 251–252.
    OpenUrlFREE Full Text
  9. ↵
    1. Brusasco V,
    2. Dinh-Xuan AT,
    3. Leff AR,
    4. et al
    . Impact factor and its role in academic promotion. Eur Respir J 2009; 34: 1499–1500.
    OpenUrlFREE Full Text
  10. ↵
    1. Relton C,
    2. Torgerson D,
    3. O'Cathain A,
    4. et al
    . Rethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" design. BMJ 2010; 340: c1066.
    OpenUrlFREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 38 Issue 5 Table of Contents
European Respiratory Journal: 38 (5)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The European Respiratory Journal makes COPD a priority
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
The European Respiratory Journal makes COPD a priority
J.B. Soriano, V. Brusasco, A.T. Dinh-Xuan
European Respiratory Journal Nov 2011, 38 (5) 999-1001; DOI: 10.1183/09031936.00055711

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The European Respiratory Journal makes COPD a priority
J.B. Soriano, V. Brusasco, A.T. Dinh-Xuan
European Respiratory Journal Nov 2011, 38 (5) 999-1001; DOI: 10.1183/09031936.00055711
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • DIAGNOSIS
    • EPIDEMIOLOGY
    • BASIC SCIENCE
    • DRUGS AND TREATMENTS
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Commemorating World Tuberculosis Day 2022
  • Is low level of vitamin D a marker of poor health or its cause?
  • Risky political game with climate change
Show more Editorial

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society